Applications for Beovu to treat diabetic macular edema have been accepted in the United States, Europe and Japan, according to a press release from Novartis.
The FDA has accepted a supplemental biologics application for Beovu (brolucizumab), the European Medicines Agency has validated a type II variation application for Beovu, and the Japanese Pharmaceuticals and Medical Devices Agency has accepted an application for Beovu, the release said.
“If approved, Beovu has the potential to provide better fluid resolution and fewer injections during the loading phase and throughout maintenance